-
公开(公告)号:JPH11181A
公开(公告)日:1999-01-06
申请号:JP8499598
申请日:1998-03-16
Applicant: HOECHST AG
Inventor: KOERNER KATHRIN , MUELLER ROLF PROF DR , SEDLACEK HANS-HARALD
IPC: C12N15/09 , A61K48/00 , A61P35/00 , C12N5/00 , C12N5/10 , C12N9/12 , C12N15/06 , C12N15/10 , C12N15/54 , C12N15/85 , C12P21/02 , C12R1/91
Abstract: PROBLEM TO BE SOLVED: To obtain a new cdc25B gene promotor comprising a sequence capable of hybridizing with a specific base sequence or a functional part thereof under a stringent condition and useful for producing a nucleic acid-constructing substance for a gene therapy, etc. SOLUTION: This new cdc25B gene promotor comprises a sequence capable of hybridizing with a sequence expressed by the formula or a functional part thereof under a stringent condition, and is capable of binding with a structural gene of an enzyme, a fused protein, a cytokine, a chemokine, a growth factor, a receptor, an antibody, a vascular formation inhibitor, a peptide, a hormone, a coagulant, a fibrinolytic protein, etc., and useful for the production of a nucleic acid-structured substance for the gene for the gene therapy of a tumoral disease, leukemia, an autoimmune disease, an allergy, an arthritis, an organ transplant rejection, a blood coagulative disease, an infection, a hormonal disease, etc. The promotor is obtained by screening a mouse genome phage library obtained from a mouse family 129FVJ.
-
公开(公告)号:JPH11178A
公开(公告)日:1999-01-06
申请号:JP2452498
申请日:1998-02-05
Applicant: HOECHST AG
Inventor: GRAULICH WOLFF , NETTELBECK DIRK , SEDLACEK HANS-HARALD , MUELLER ROLF
IPC: C12N15/09 , A61K38/00 , A61K38/17 , A61K38/19 , A61K39/00 , A61K39/395 , A61K48/00 , A61P7/02 , A61P7/06 , A61P9/00 , A61P25/00 , A61P29/00 , A61P31/00 , A61P35/02 , A61P37/00 , A61P37/08 , C07K14/52 , C07K14/705 , C12N5/10 , C12N15/00 , C12N15/11 , C12N15/12 , C12N15/85 , C12R1/91
Abstract: PROBLEM TO BE SOLVED: To provide a new human endoglin gene promoter containing a specific sequence, a functional part or variant, capable of controlling the transcription and translation of an effector gene and useful for gene therapy, etc. SOLUTION: This new human endoglin gene promoter contains the sequence expressed by the formula, its functional part or its variant and is capable of controlling the transcription and translation of an effector gene inserted into a cell. It is useful as a strong and endothelially specific promoter capable of producing an agent for the treatment of tumors, leukemia, autoimmune diseases, allergy, arthritis, inflammation, rejection of organs, graft versus host reaction, blood coagulation diseases, cardiovascular diseases, anemia, infection, CNS damage, etc., and usable for gene therapy. The promoter can be produced by cloning a human endoglin cDNA with a promoter finder DNA working kit.
-
公开(公告)号:JPS61212590A
公开(公告)日:1986-09-20
申请号:JP5159586
申请日:1986-03-11
Applicant: HOECHST AG
Inventor: SCHEUNEMANN KARL-HEINZ , DUERCKHEIMER WALTER , BLUMBACH JUERGEN , LIMBERT MICHAEL , SCHORLEMMER HANS-ULRICH , DICKNEITE GERHARD , SEDLACEK HANS-HARALD
IPC: A61K31/33 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/455 , A61K31/465 , A61K31/53 , A61P31/04 , A61P35/00 , A61P37/00 , A61P37/04 , A61P43/00 , C07D211/54 , C07D211/84 , C07D213/80 , C07D231/18 , C07D235/28 , C07D237/18 , C07D239/38 , C07D241/18 , C07D249/12 , C07D253/06 , C07D253/07 , C07D277/20 , C07D277/32 , C07D277/36 , C07D277/46 , C07D277/56 , C07D277/70 , C07D277/74 , C07D285/12 , C07D285/125 , C07D521/00
-
公开(公告)号:JPH10229888A
公开(公告)日:1998-09-02
申请号:JP3640898
申请日:1998-02-18
Applicant: HOECHST AG
Inventor: MUELLER ROLF PROF DR , LIU NINGSHU , ZWICKER JOERK DR , SEDLACEK HANS-HARALD
IPC: C12N15/09 , A61K31/70 , A61K48/00 , A61P7/02 , A61P9/00 , A61P25/00 , A61P29/00 , A61P31/00 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07K14/47 , C12N5/10 , C12N15/85
Abstract: PROBLEM TO BE SOLVED: To obtain a nucleic acid structure for cell cycle regulation and expression of a structural gene. SOLUTION: This nucleic acid structure comprises an activator sequence, a chimera promoter module containing a nucleotide sequence connecting a protein of E2F family to a protein of CDF-1 family and a structural gene, and the chimera promoter module brings about up-regulation of gene expression in a cell cycle, which is slower than that of B-myb promoter, but faster than that of cdc25C promoter and the protein CDF-1.
-
公开(公告)号:JPH104980A
公开(公告)日:1998-01-13
申请号:JP4477297
申请日:1997-02-13
Applicant: HOECHST AG
Inventor: MUELLER ROLF , ZWICKER JOERK , SEDLACEK HANS-HARALD
IPC: C12N15/09 , A61K38/18 , A61K38/19 , A61K48/00 , C12N5/10 , C12N15/18 , C12N15/19 , C12N15/52 , C12N15/74 , C12N15/79 , C12N15/85
Abstract: PROBLEM TO BE SOLVED: To obtain the subject new structure useful for gene therapy, etc., containing an activator sequence, a promotor module of a specific base sequence and a gene coding for an active substance to be expressed depending on cell cycle and capable of controlling a cell cycle-depending expression. SOLUTION: This new nucleic acid structure is effective on cell cycledepending expression of at least one kind of gene including the following components: (A) an activator sequence, (B) a promotor module having a nucleotide sequence to be linked with at least one kind of protein of the E2F family and another nucleotide sequence to be linked with at least one kind of protein of the CHF family and (C) a gene coding for an active substance expressed depending on cell cycle. The structure is useful for gene therapy, etc., for an autoimmune disease, an infectious disease, an allergy, an inflammatory disease, etc. The structure is obtained by combining a promotor module and a gene coding for an active substance expressed depending on a cell cycle with a cell- specific activator sequence.
-
公开(公告)号:JPH11169A
公开(公告)日:1999-01-06
申请号:JP33050897
申请日:1997-12-01
Applicant: HOECHST AG
Inventor: SEDLACEK HANS-HARALD , MUELLER ROLF
IPC: C12N15/09 , A61K48/00 , C07K16/28 , C07K16/44 , C12N5/10 , C12N9/24 , C12N15/79 , C12N15/85 , C12N15/87
Abstract: PROBLEM TO BE SOLVED: To obtain a polyfunctional ligand system that is not immnunogenic, can be readily prepared and used, and is useful as pharmaceuticals, by allowing the system to include a target cell-specific ligand and a (partially) antibody- containing gene structure-specific ligand. SOLUTION: The target cell-specific ligand linking to the cell surfaces of one or more target cells as growth factor, cytokine, interferon or the like and one or more gene constitution specific ligand including an antibody or its part as F(ab)2 fragment or the like are allowed to link to each other to prepare the objective polyfunctional ligand system containing synthetic fusion-induced peptide or cell fusion induced peptide, but it is not immunogenic. This ligand system is preferably used to produce a therapeutic and preventive drugs for skin diseases, mucous membrane diseases, neurosystem diseases, internal diseases and the like.
-
公开(公告)号:JPH104979A
公开(公告)日:1998-01-13
申请号:JP2946297
申请日:1997-02-13
Applicant: HOECHST AG
Inventor: SEDLACEK HANS-HARALD , KLENK HANS-DIETER , KISSEL THOMAS , MUELLER ROLF
IPC: C12N15/09 , A61K35/76 , A61K38/00 , A61K38/16 , A61K38/18 , A61K38/28 , A61K39/395 , A61K39/42 , A61K47/48 , A61K48/00 , A61P31/12 , A61P35/00 , C07H21/04 , C12N15/63 , C12N15/79 , C12N15/85 , C12N15/87 , C12N15/88
Abstract: PROBLEM TO BE SOLVED: To obtain the subject new vector containing a non-viral carrier for a gene transfer, a ligand capable of being bound to a target cell, a fused protein for penetrating the vector into the target cell, and the transferred, useful for the gene transfer into the cell, and capable of being used for genetic therapies, etc. SOLUTION: This new vector is used for inserting at least one gene into the cell of an organism, is specific to the target cell, and contains the following components: (A) a non-viral carrier for the gene to be inserted, (B) a ligand capable of being specifically bound to the desired target cell, (C) a fused protein or peptide for penetrating the vector in the cytoplasm of the target cell, and (D) the gene to be transferred. The new vector is useful as a vector for genetic therapies, etc. The vector is obtained by combining albumin, etc., with a plasmid containing the gene to be transferred and subsequently complexing the obtained compler with a monoclonal antibody capable of being bound to a target cell and with a viral fused protein capable of permeating into the cell.
-
公开(公告)号:GR3033535T3
公开(公告)日:2000-09-29
申请号:GR20000401227
申请日:2000-05-31
Applicant: HOECHST AG
Inventor: SEDLACEK HANS-HARALD , MUELLER ROLF
IPC: C12N15/09 , A61K9/127 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/44 , A61K38/46 , A61K38/55 , A61K39/395 , A61K47/48 , A61K48/00 , A61P7/02 , A61P9/08 , A61P25/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K14/475 , C12N15/00 , C12N15/85 , C12P21/02 , C12R1/91 , C12R1/92 , C12N15/86
Abstract: PCT No. PCT/EP95/03370 Sec. 371 Date Apr. 18, 1997 Sec. 102(e) Date Apr. 18, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06940 PCT Pub. Date Mar. 7, 1996A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.
-
公开(公告)号:DE59508145D1
公开(公告)日:2000-05-11
申请号:DE59508145
申请日:1995-08-25
Applicant: HOECHST AG
Inventor: SEDLACEK HANS-HARALD , MUELLER ROLF
IPC: C12N15/09 , A61K9/127 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/44 , A61K38/46 , A61K38/55 , A61K39/395 , A61K47/48 , A61K48/00 , A61P7/02 , A61P9/08 , A61P25/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K14/475 , C12N15/00 , C12N15/85 , C12P21/02 , C12R1/91 , C12R1/92 , C12N15/86 , C12N15/88
Abstract: PCT No. PCT/EP95/03370 Sec. 371 Date Apr. 18, 1997 Sec. 102(e) Date Apr. 18, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06940 PCT Pub. Date Mar. 7, 1996A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.
-
公开(公告)号:AT191506T
公开(公告)日:2000-04-15
申请号:AT95930524
申请日:1995-08-25
Applicant: HOECHST AG
Inventor: SEDLACEK HANS-HARALD , MUELLER ROLF
IPC: C12N15/09 , A61K9/127 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/44 , A61K38/46 , A61K38/55 , A61K39/395 , A61K47/48 , A61K48/00 , A61P7/02 , A61P9/08 , A61P25/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K14/475 , C12N15/00 , C12N15/85 , C12P21/02 , C12R1/91 , C12R1/92 , C12N15/86
Abstract: PCT No. PCT/EP95/03370 Sec. 371 Date Apr. 18, 1997 Sec. 102(e) Date Apr. 18, 1997 PCT Filed Aug. 25, 1995 PCT Pub. No. WO96/06940 PCT Pub. Date Mar. 7, 1996A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.
-
-
-
-
-
-
-
-
-